Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Exane BNP Paribas Initiates Coverage On Steven Madden with Outperform Rating

Exane BNP Paribas analyst Aubrey Tianello initiates coverage on Steven Madden (NASDAQ:SHOO) with a Outperform rating.
byBenzinga Newsdesk
September 21, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Exane BNP Paribas analyst Aubrey Tianello initiates coverage on Steven Madden (NASDAQ:SHOO) with a Outperform rating.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

Aligos Therapeutics To Present Multiple Posters At AASLD’s The Liver Meeting 2023, Highlighting Progress For Its Clinical Stage Portfolio, including Lead THR-β Agonist For The Treatment Of NASH, ALG-055009; ALG-000184, The Company’s Lead CAM-E Molecule

By Benzinga Newsdesk
November 7, 9:08 AM
Aligos Therapeutics, Inc. (NASDAQ:ALGS, "Aligos")))), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced that

ALGS